cached image

William E. Fantegrossi, Ph.D. - Publications

Affiliations: 
Pharmacology & Toxicology University of Arkansas for Medical Sciences, United States 
Area:
behavioral pharmacology, emerging drugs of abuse, hallucinogens, drug discrimination, drug self-administration
Website:
http://pharmtox.uams.edu/faculty/primary-faculty/william-e-fantegrossi-ph-d/

86 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 McClenahan SJ, Gunnell MG, Owens SM, Fantegrossi WE. Active vaccination reduces reinforcing effects of MDPV in male Sprague-Dawley rats trained to self-administer cocaine. Psychopharmacology. PMID 32500210 DOI: 10.1007/s00213-020-05558-0  0.56
2020 Hay CE, Ewing LE, Hambuchen MD, Zintner SM, Small JC, Bolden CT, Fantegrossi WE, Margaritis P, Owens SM, Peterson EC. The development and characterization of an scFv-Fc fusion based gene therapy to reduce the psychostimulant effects of methamphetamine abuse. The Journal of Pharmacology and Experimental Therapeutics. PMID 32245884 DOI: 10.1124/jpet.119.261180  0.56
2020 Hyatt WS, Hirsh CE, Russell LN, Chitre NM, Murnane KS, Rice KC, Fantegrossi WE. The synthetic cathinone 3,4-methylenedioxypyrovalerone increases impulsive action in rats. Behavioural Pharmacology. PMID 32101987 DOI: 10.1097/FBP.0000000000000548  1
2020 Jones S, Yarbrough AL, Fantegrossi WE, Prather PL, Bush JM, Radominska-Pandya A, Fujiwara R. Identifying cytochrome P450s involved in oxidative metabolism of synthetic cannabinoid N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indole-3-carboxamide (STS-135). Pharmacology Research & Perspectives. 8: e00561. PMID 32003945 DOI: 10.1002/prp2.561  0.88
2020 Berquist MD, Leth-Petersen S, Kristensen JL, Fantegrossi WE. In vivo effects of 3,4-methylenedioxymethamphetamine (MDMA) and its deuterated form in rodents: Drug discrimination and thermoregulation. Drug and Alcohol Dependence. 208: 107850. PMID 31954950 DOI: 10.1016/j.drugalcdep.2020.107850  1
2019 Berquist MD, Leth-Petersen S, Kristensen JL, Fantegrossi WE. Locomotor effects of 3,4-methylenedioxymethamphetamine (MDMA) and its deuterated form in mice: psychostimulant effects, stereotypy, and sensitization. Psychopharmacology. PMID 31729537 DOI: 10.1007/s00213-019-05380-3  1
2019 Hyatt WS, Berquist MD, Chitre NM, Russell LN, Rice KC, Murnane KS, Fantegrossi WE. Repeated administration of synthetic cathinone 3,4-methylenedioxypyrovalerone persistently increases impulsive choice in rats. Behavioural Pharmacology. PMID 31211703 DOI: 10.1097/FBP.0000000000000492  1
2019 Griffin BA, Caperton CO, Russell LN, Cabalong CV, Wilson CD, Urquhart KR, Martins BS, Zita MD, Patton AL, Alund AW, Owens SM, Fantegrossi WE, Moran JH, Brents LK. exposure to norbuprenorphine, a major metabolite of buprenorphine, induces fetal opioid dependence and leads to neonatal opioid withdrawal syndrome. The Journal of Pharmacology and Experimental Therapeutics. PMID 31028107 DOI: 10.1124/jpet.118.254219  1
2019 Ford BM, Cabanlong CV, Tai S, Franks LN, Penthala NR, Crooks PA, Prather PL, Fantegrossi WE. Reduced tolerance and asymmetrical cross-tolerance to effects of indole quinuclidinone analogue PNR-4-20, a G protein biased CB1R agonist in mice: comparisons with Δ9-THC and JWH-018. The Journal of Pharmacology and Experimental Therapeutics. PMID 30833484 DOI: 10.1124/jpet.118.252965  1
2019 Jones S, Yarbrough AL, Shoeib A, Bush JM, Fantegrossi WE, Prather PL, Radominska-Pandya A, Fujiwara R. Enzymatic Analysis of Glucuronidation of Synthetic Cannabinoid 1-Naphthyl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (FDU-PB-22). Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 1-25. PMID 30739533 DOI: 10.1080/00498254.2019.1580403  0.88
2018 Wilson CD, Tai S, Ewing L, Crane J, Lockhart T, Yarbrough AL, Fujiwara R, Radominska-Pandya A, Fantegrossi WE. Convulsant effects of abused synthetic cannabinoids JWH-018 and 5F-AB-PINACA are mediated by agonist actions at CB1 receptors in mice. The Journal of Pharmacology and Experimental Therapeutics. PMID 30420360 DOI: 10.1124/jpet.118.251157  1
2018 Hutchison RD, Ford BM, Franks LN, Wilson CD, Yarbrough AL, Fujiwara R, Su MK, Fernandez D, James LP, Moran JH, Patton AL, Fantegrossi WE, Radominska-Pandya A, Prather PL. Atypical Pharmacodynamic Properties and Metabolic Profile of the Abused Synthetic Cannabinoid AB-PINACA: Potential Contribution to Pronounced Adverse Effects Relative to Δ-THC. Frontiers in Pharmacology. 9: 1084. PMID 30319418 DOI: 10.3389/fphar.2018.01084  0.92
2018 Tai S, Vasiljevik T, Sherwood AM, Eddington S, Wilson CD, Prisinzano TE, Fantegrossi WE. Assessment of rimonabant-like adverse effects of purported CB1R neutral antagonist / CB2R agonist aminoalkylindole derivatives in mice. Drug and Alcohol Dependence. 192: 285-293. PMID 30300803 DOI: 10.1016/j.drugalcdep.2018.08.011  1
2018 Yadlapalli JSK, Bommagani SB, Mahelona RD, Wan A, Gannon BM, Penthala NR, Dobretsov M, Crooks PA, Fantegrossi WE. Evaluation of morphine-like effects of the mixed mu/delta agonist morphine-6--sulfate in rats: Drug discrimination and physical dependence. Pharmacology Research & Perspectives. 6: e00403. PMID 29930811 DOI: 10.1002/prp2.403  1
2018 Patton AL, Seely KA, Yarbrough AL, Fantegrossi W, James LP, McCain KR, Fujiwara R, Prather PL, Moran JH, Radominska-Pandya A. Altered metabolism of synthetic cannabinoid JWH-018 by human cytochrome P450 2C9 and variants. Biochemical and Biophysical Research Communications. PMID 29522717 DOI: 10.1016/j.bbrc.2018.03.028  0.88
2018 Fantegrossi WE, Wilson CD, Berquist MD. Pro-psychotic effects of synthetic cannabinoids: interactions with central dopamine, serotonin, and glutamate systems. Drug Metabolism Reviews. 1-9. PMID 29385930 DOI: 10.1080/03602532.2018.1428343  1
2017 Gannon BM, Williamson A, Rice KC, Fantegrossi WE. Role of monoaminergic systems and ambient temperature in bath salts constituent 3,4-methylenedioxypyrovalerone (MDPV) elicited hyperthermia and locomotor stimulation in mice. Neuropharmacology. PMID 28887185 DOI: 10.1016/j.neuropharm.2017.09.004  1
2017 Gannon BM, Russell LN, Modi MS, Rice KC, Fantegrossi WE. Effects of orally self-administered bath salt constituent 3,4-methylenedioxypyrovalerone (MDPV) in mice. Drug and Alcohol Dependence. 179: 408-415. PMID 28866386 DOI: 10.1016/j.drugalcdep.2017.06.031  1
2017 Ford BM, Franks LN, Tai S, Fantegrossi WE, Stahl EL, Berquist MD, Cabanlong CV, Wilson CD, Penthala NR, Crooks PA, Prather PL. Characterization of Structurally Novel G Protein Biased CB1 Agonists: Implications for Drug Development. Pharmacological Research. PMID 28838808 DOI: 10.1016/j.phrs.2017.08.008  1
2017 Berquist MD, Hyatt WS, Bauer-Erickson J, Gannon BM, Norwood AP, Fantegrossi WE. Phencyclidine-like in vivo effects of methoxetamine in mice and rats. Neuropharmacology. PMID 28830759 DOI: 10.1016/j.neuropharm.2017.08.028  1
2017 Berquist MD, Fantegrossi WE. Discriminative Stimulus Effects of Psychostimulants. Current Topics in Behavioral Neurosciences. PMID 28341944 DOI: 10.1007/7854_2017_5  1
2017 Ford BM, Tai S, Fantegrossi WE, Prather PL. Synthetic Pot: Not Your Grandfather's Marijuana. Trends in Pharmacological Sciences. PMID 28162792 DOI: 10.1016/j.tips.2016.12.003  1
2016 Gannon BM, Fantegrossi WE. Cocaine-Like Discriminative Stimulus Effects of Mephedrone and Naphyrone in Mice. Journal of Drug and Alcohol Research. 5. PMID 28424752 DOI: 10.4303/jdar/236009  1
2016 Tai S, Fantegrossi WE. Pharmacological and Toxicological Effects of Synthetic Cannabinoids and Their Metabolites. Current Topics in Behavioral Neurosciences. PMID 28012093 DOI: 10.1007/7854_2016_60  1
2016 Farrell MS, McCorvy JD, Huang XP, Urban DJ, White KL, Giguere PM, Doak AK, Bernstein AI, Stout KA, Park SM, Rodriguiz RM, Gray BW, Hyatt WS, Norwood AP, Webster KA, ... ... Fantegrossi WE, et al. In Vitro and In Vivo Characterization of the Alkaloid Nuciferine. Plos One. 11: e0150602. PMID 26963248 DOI: 10.1371/journal.pone.0150602  1
2016 Gannon BM, Williamson A, Suzuki M, Rice KC, Fantegrossi WE. Stereoselective effects of abused "bath salt" constituent 3,4-methylenedioxypyrovalerone in mice: Drug discrimination, locomotor activity, and thermoregulation Journal of Pharmacology and Experimental Therapeutics. 356: 615-623. DOI: 10.1124/jpet.115.229500  1
2015 Tai S, Hyatt WS, Gu C, Franks LN, Vasiljevik T, Brents LK, Prather PL, Fantegrossi WE. Repeated administration of phytocannabinoid Δ(9)-THC or synthetic cannabinoids JWH-018 and JWH-073 induces tolerance to hypothermia but not locomotor suppression in mice, and reduces CB1 receptor expression and function in a brain region-specific manner. Pharmacological Research. 102: 22-32. PMID 26361728 DOI: 10.1016/j.phrs.2015.09.006  1
2015 Fantegrossi WE, Gray BW, Bailey JM, Smith DA, Hansen M, Kristensen JL. Hallucinogen-like effects of 2-([2-(4-cyano-2,5-dimethoxyphenyl) ethylamino]methyl)phenol (25CN-NBOH), a novel N-benzylphenethylamine with 100-fold selectivity for 5-HT₂A receptors, in mice. Psychopharmacology. 232: 1039-47. PMID 25224567 DOI: 10.1007/s00213-014-3739-3  1
2014 Gannon BM, Reichard EE, Fantegrossi WE. Psychostimulant Abuse and HIV Infection: cocaine, methamphetamine, and "bath salts" cathinone analogues. Current Addiction Reports. 1: 237-242. PMID 26413453 DOI: 10.1007/s40429-014-0025-8  1
2014 Tai S, Fantegrossi WE. Synthetic Cannabinoids: Pharmacology, Behavioral Effects, and Abuse Potential. Current Addiction Reports. 1: 129-136. PMID 26413452 DOI: 10.1007/s40429-014-0014-y  1
2014 Baumann MH, Solis E, Watterson LR, Marusich JA, Fantegrossi WE, Wiley JL. Baths salts, spice, and related designer drugs: the science behind the headlines. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 34: 15150-8. PMID 25392483 DOI: 10.1523/JNEUROSCI.3223-14.2014  1
2014 Smith DA, Bailey JM, Williams D, Fantegrossi WE. Tolerance and cross-tolerance to head twitch behavior elicited by phenethylamine- and tryptamine-derived hallucinogens in mice. The Journal of Pharmacology and Experimental Therapeutics. 351: 485-91. PMID 25271256 DOI: 10.1124/jpet.114.219337  1
2014 Marshell R, Kearney-Ramos T, Brents LK, Hyatt WS, Tai S, Prather PL, Fantegrossi WE. In vivo effects of synthetic cannabinoids JWH-018 and JWH-073 and phytocannabinoid Δ9-THC in mice: inhalation versus intraperitoneal injection. Pharmacology, Biochemistry, and Behavior. 124: 40-7. PMID 24857780 DOI: 10.1016/j.pbb.2014.05.010  1
2014 Hyatt WS, Fantegrossi WE. Δ9-THC exposure attenuates aversive effects and reveals appetitive effects of K2/'Spice' constituent JWH-018 in mice Behavioural Pharmacology. 25: 253-257. PMID 24625557 DOI: 10.1097/FBP.0000000000000034  1
2014 Patton AL, Seely KA, Pulla S, Rusch NJ, Moran CL, Fantegrossi WE, Knight LD, Marraffa JM, Kennedy PD, James LP, Endres GW, Moran JH. Quantitative measurement of acetyl fentanyl and acetyl norfentanyl in human urine by LC-MS/MS. Analytical Chemistry. 86: 1760-6. PMID 24354295 DOI: 10.1021/ac4036197  1
2014 Fantegrossi WE, Moran JH, Radominska-Pandya A, Prather PL. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity? Life Sciences. 97: 45-54. PMID 24084047 DOI: 10.1016/j.lfs.2013.09.017  1
2014 Norwood AP, Al-Chaer ED, Fantegrossi WE. Predisposing effects of neonatal visceral pain on abuse-related effects of morphine in adult male Sprague Dawley rats Psychopharmacology. DOI: 10.1007/s00213-014-3574-6  1
2013 Seely KA, Patton AL, Moran CL, Womack ML, Prather PL, Fantegrossi WE, Radominska-Pandya A, Endres GW, Channell KB, Smith NH, McCain KR, James LP, Moran JH. Forensic investigation of K2, Spice, and "bath salt" commercial preparations: a three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds. Forensic Science International. 233: 416-22. PMID 24314548 DOI: 10.1016/j.forsciint.2013.10.002  1
2013 Fantegrossi WE, McCain KR, Moran JH, Hoffman RS. Not simply synthetic tetrahydrocannabinol Journal of Pediatrics. 163: 1797-1798. PMID 24128645 DOI: 10.1016/j.jpeds.2013.09.017  1
2013 Patton AL, Seely KA, Chimalakonda KC, Tran JP, Trass M, Miranda A, Fantegrossi WE, Kennedy PD, Dobrowolski P, Radominska-Pandya A, McCain KR, James LP, Endres GW, Moran JH. Targeted metabolomic approach for assessing human synthetic cannabinoid exposure and pharmacology. Analytical Chemistry. 85: 9390-9. PMID 23987522 DOI: 10.1021/ac4024704  1
2013 Brents LK, Zimmerman SM, Saffell AR, Prather PL, Fantegrossi WE. Differential drug-drug interactions of the synthetic cannabinoids JWH-018 and JWH-073: Implications for drug abuse liability and pain therapys Journal of Pharmacology and Experimental Therapeutics. 346: 350-361. PMID 23801678 DOI: 10.1124/jpet.113.206003  1
2013 Vasiljevik T, Franks LN, Ford BM, Douglas JT, Prather PL, Fantegrossi WE, Prisinzano TE. Design, synthesis, and biological evaluation of aminoalkylindole derivatives as cannabinoid receptor ligands with potential for treatment of alcohol abuse. Journal of Medicinal Chemistry. 56: 4537-50. PMID 23631463 DOI: 10.1021/jm400268b  1
2013 Fantegrossi WE, Gannon BM, Zimmerman SM, Rice KC. In vivo effects of abused 'bath salt' constituent 3,4- methylenedioxypyrovalerone (MDPV) in mice: Drug discrimination, thermoregulation, and locomotor activity Neuropsychopharmacology. 38: 563-573. PMID 23212455 DOI: 10.1038/npp.2012.233  1
2013 Fantegrossi WE, Xiao WR, Zimmerman SM. Novel technology for modulating locomotor activity as an operant response in the mouse: Implications for neuroscience studies involving " exercise" in rodents Journal of Neuroscience Methods. 212: 338-343. PMID 23164960 DOI: 10.1016/j.jneumeth.2012.10.020  1
2013 Nichols DE, Fantegrossi WE. Emerging Designer Drugs The Effects of Drug Abuse On the Human Nervous System. 575-596. DOI: 10.1016/B978-0-12-418679-8.00019-8  1
2012 Seely KA, Brents LK, Franks LN, Rajasekaran M, Zimmerman SM, Fantegrossi WE, Prather PL. AM-251 and rimonabant act as direct antagonists at mu-opioid receptors: Implications for opioid/cannabinoid interaction studies Neuropharmacology. 63: 905-915. PMID 22771770 DOI: 10.1016/j.neuropharm.2012.06.046  1
2012 Brents LK, Gallus-Zawada A, Radominska-Pandya A, Vasiljevik T, Prisinzano TE, Fantegrossi WE, Moran JH, Prather PL. Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity Biochemical Pharmacology. 83: 952-961. PMID 22266354 DOI: 10.1016/j.bcp.2012.01.004  1
2012 Murnane KS, Perrine SA, Finton BJ, Galloway MP, Howell LL, Fantegrossi WE. Effects of exposure to amphetamine derivatives on passive avoidance performance and the central levels of monoamines and their metabolites in mice: correlations between behavior and neurochemistry. Psychopharmacology. 220: 495-508. PMID 21993877 DOI: 10.1007/s00213-011-2504-0  1
2011 Brents LK, Reichard EE, Zimmerman SM, Moran JH, Fantegrossi WE, Prather PL. Phase i hydroxylated metabolites of the k2 synthetic cannabinoid jwh-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity Plos One. 6. PMID 21755008 DOI: 10.1371/journal.pone.0021917  1
2011 Moran CL, Le VH, Chimalakonda KC, Smedley AL, Lackey FD, Owen SN, Kennedy PD, Endres GW, Ciske FL, Kramer JB, Kornilov AM, Bratton LD, Dobrowolski PJ, Wessinger WD, Fantegrossi WE, et al. Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urine Analytical Chemistry. 83: 4228-4236. PMID 21506519 DOI: 10.1021/ac2005636  1
2011 Matsumoto RR, Li SM, Katz JL, Fantegrossi WE, Coop A. Effects of the selective sigma receptor ligand, 1-(2-phenethyl)piperidine oxalate (AC927), on the behavioral and toxic effects of cocaine. Drug and Alcohol Dependence. 118: 40-7. PMID 21420799 DOI: 10.1016/j.drugalcdep.2011.02.017  1
2011 Kalechstein A, Fantegrossi WE, Cowan RL, Mahoney JJ. Mdma Neuropsychology and Substance Use: State-of-the-Art and Future Directions. 171-206. DOI: 10.4324/9780203837719  0.68
2011 Bisagno V, Fantegrossi WE, Urbano FJ. Translational Studies in Drug Abuse Translational Neuroscience: a Guide to a Successful Program. 67-82. DOI: 10.1002/9781118260470.ch5  1
2010 Fantegrossi WE, Simoneau J, Cohen MS, Zimmerman SM, Henson CM, Rice KC, Woods JH. Interaction of 5-HT2A and 5-HT2C receptors in R(-)-2,5-dimethoxy-4-iodoamphetamine-elicited head twitch behavior in mice. The Journal of Pharmacology and Experimental Therapeutics. 335: 728-34. PMID 20858706 DOI: 10.1124/jpet.110.172247  1
2010 Murnane KS, Fantegrossi WE, Godfrey JR, Banks ML, Howell LL. Endocrine and neurochemical effects of 3,4-methylenedioxymethamphetamine and its stereoisomers in rhesus monkeys. The Journal of Pharmacology and Experimental Therapeutics. 334: 642-50. PMID 20466795 DOI: 10.1124/jpet.110.166595  1
2010 McClung J, Fantegrossi W, Howell LL. Reinstatement of extinguished amphetamine self-administration by 3,4-methylenedioxymethamphetamine (MDMA) and its enantiomers in rhesus monkeys. Psychopharmacology. 210: 75-83. PMID 20309529 DOI: 10.1007/s00213-010-1818-7  1
2010 LeGendre O, Pecic S, Chaudhary S, Zimmerman SM, Fantegrossi WE, Harding WW. Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine Bioorganic and Medicinal Chemistry Letters. 20: 628-631. PMID 19963380 DOI: 10.1016/j.bmcl.2009.11.053  1
2009 Murnane KS, Murai N, Howell LL, Fantegrossi WE. Discriminative stimulus effects of psychostimulants and hallucinogens in S(+)-3,4-methylenedioxymethamphetamine (MDMA) and R(-)-MDMA trained mice. The Journal of Pharmacology and Experimental Therapeutics. 331: 717-23. PMID 19684254 DOI: 10.1124/jpet.109.156174  1
2009 Fantegrossi WE, Bauzo RM, Manvich DM, Morales JC, Votaw JR, Goodman MM, Howell LL. Role of dopamine transporters in the behavioral effects of 3,4-methylenedioxymethamphetamine (MDMA) in nonhuman primates. Psychopharmacology. 205: 337-47. PMID 19421742 DOI: 10.1007/s00213-009-1545-0  1
2009 Goeders JE, Murnane KS, Banks ML, Fantegrossi WE. Escalation of food-maintained responding and sensitivity to the locomotor stimulant effects of cocaine in mice. Pharmacology, Biochemistry, and Behavior. 93: 67-74. PMID 19376153 DOI: 10.1016/j.pbb.2009.04.008  1
2009 Ko MC, Woods JH, Fantegrossi WE, Galuska CM, Wichmann J, Prinssen EP. Behavioral effects of a synthetic agonist selective for nociceptin/orphanin FQ peptide receptors in monkeys. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 34: 2088-96. PMID 19279568 DOI: 10.1038/npp.2009.33  1
2009 Fantegrossi WE, Murai N, Mathúna BO, Pizarro N, De La Torre R. Discriminative stimulus effects of 3,4-methylenedioxymethamphetamine and its enantiomers in mice: Pharmacokinetic considerations Journal of Pharmacology and Experimental Therapeutics. 329: 1006-1015. PMID 19276400 DOI: 10.1124/jpet.109.150573  1
2008 Negus SS, Fantegrossi W. Overview of conference on preclinical abuse liability testing: current methods and future challenges Drug and Alcohol Dependence. 92: 301-306. PMID 18286703 DOI: 10.1016/j.drugalcdep.2007.05.001  1
2008 Fantegrossi WE. In Vivo Pharmacology of MDMA and Its Enantiomers in Rhesus Monkeys Experimental and Clinical Psychopharmacology. 16: 1-12. PMID 18266547 DOI: 10.1037/1064-1297.16.1.1  1
2008 Fantegrossi WE, Ciullo JR, Wakabayashi KT, De La Garza R, Traynor JR, Woods JH. A comparison of the physiological, behavioral, neurochemical and microglial effects of methamphetamine and 3,4-methylenedioxymethamphetamine in the mouse. Neuroscience. 151: 533-43. PMID 18082974 DOI: 10.1016/j.neuroscience.2007.11.007  1
2008 Fantegrossi WE, Murnane KS, Reissig CJ. The behavioral pharmacology of hallucinogens. Biochemical Pharmacology. 75: 17-33. PMID 17977517 DOI: 10.1016/j.bcp.2007.07.018  1
2008 Fantegrossi WE, Reissig CJ, Katz EB, Yarosh HL, Rice KC, Winter JC. Hallucinogen-like effects of N,N-dipropyltryptamine (DPT): Possible mediation by serotonin 5-HT1A and 5-HT2A receptors in rodents Pharmacology Biochemistry and Behavior. 88: 358-365. PMID 17905422 DOI: 10.1016/j.pbb.2007.09.007  1
2007 Weerts EM, Fantegrossi WE, Goodwin AK. The value of nonhuman primates in drug abuse research. Experimental and Clinical Psychopharmacology. 15: 309-27. PMID 17696678 DOI: 10.1037/1064-1297.15.4.309  1
2007 Yarosh HL, Katz EB, Coop A, Fantegrossi WE. MDMA-like behavioral effects of N-substituted piperazines in the mouse Pharmacology Biochemistry and Behavior. 88: 18-27. PMID 17651790 DOI: 10.1016/j.pbb.2007.06.007  1
2007 Kalechstein AD, De La Garza R, Mahoney JJ, Fantegrossi WE, Newton TF. MDMA use and neurocognition: a meta-analytic review. Psychopharmacology. 189: 531-7. PMID 17082969 DOI: 10.1007/s00213-006-0601-2  1
2007 Fantegrossi WE. Reinforcing effects of methylenedioxy amphetamine congeners in rhesus monkeys: Are intravenous self-administration experiments relevant to MDMA neurotoxicity? Psychopharmacology. 189: 471-482. PMID 16555062 DOI: 10.1007/s00213-006-0320-8  1
2006 Fantegrossi WE, Harrington AW, Kiessel CL, Eckler JR, Rabin RA, Winter JC, Coop A, Rice KC, Woods JH. Hallucinogen-like actions of 5-methoxy-N,N-diisopropyltryptamine in mice and rats. Pharmacology, Biochemistry, and Behavior. 83: 122-9. PMID 16460788 DOI: 10.1016/j.pbb.2005.12.015  1
2005 Fantegrossi WE, Kugle KM, Valdes LJ, Koreeda M, Woods JH. Kappa-opioid receptor-mediated effects of the plant-derived hallucinogen, salvinorin A, on inverted screen performance in the mouse. Behavioural Pharmacology. 16: 627-33. PMID 16286814  1
2005 Fantegrossi WE, Kiessel CL, De la Garza R, Woods JH. Serotonin synthesis inhibition reveals distinct mechanisms of action for MDMA and its enantiomers in the mouse. Psychopharmacology. 181: 529-36. PMID 15983787 DOI: 10.1007/s00213-005-0005-8  1
2005 Fantegrossi WE, Harrington AW, Eckler JR, Arshad S, Rabin RA, Winter JC, Coop A, Rice KC, Woods JH. Hallucinogen-like actions of 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) in mice and rats. Psychopharmacology. 181: 496-503. PMID 15983786 DOI: 10.1007/s00213-005-0009-4  1
2005 Fantegrossi WE, Ko MC, Woods JH, Richelson E. Antinociceptive, hypothermic, hypotensive, and reinforcing effects of a novel neurotensin receptor agonist, NT69L, in rhesus monkeys. Pharmacology, Biochemistry, and Behavior. 80: 341-9. PMID 15680187 DOI: 10.1016/j.pbb.2004.12.005  1
2005 Fantegrossi WE, Winger G, Woods JH, Woolverton WL, Coop A. Reinforcing and discriminative stimulus effects of 1-benzylpiperazine and trifluoromethylphenylpiperazine in rhesus monkeys. Drug and Alcohol Dependence. 77: 161-8. PMID 15664717 DOI: 10.1016/j.drugalcdep.2004.07.014  1
2004 Parrott AC, Fantegrossi WE, Woods JH, Winger G, Kilbourn M, Sherman P, Woolverton WL, Yuan J, Hatzidimitriou G, Ricaurte GA. MDMA and the loss of reinforcement in Fantegrossi et al (2004) (multiple letters) Neuropsychopharmacology. 29: 1940-1942. PMID 15383828 DOI: 10.1038/sj.npp.1300538  1
2004 Fantegrossi WE, Woods JH, Winger G. Transient reinforcing effects of phenylisopropylamine and indolealkylamine hallucinogens in rhesus monkeys. Behavioural Pharmacology. 15: 149-57. PMID 15096915 DOI: 10.1097/00008877-200403000-00007  1
2004 Fantegrossi WE, Woolverton WL, Kilbourn M, Sherman P, Yuan J, Hatzidimitriou G, Ricaurte GA, Woods JH, Winger G. Behavioral and neurochemical consequences of long-term intravenous self-administration of MDMA and its enantiomers by rhesus monkeys. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 29: 1270-81. PMID 15039771 DOI: 10.1038/sj.npp.1300442  1
2004 Fantegrossi WE, Kiessel CL, Leach PT, Van Martin C, Karabenick RL, Chen X, Ohizumi Y, Ullrich T, Rice KC, Woods JH. Nantenine: an antagonist of the behavioral and physiological effects of MDMA in mice. Psychopharmacology. 173: 270-7. PMID 14740148 DOI: 10.1007/s00213-003-1741-2  1
2003 Fantegrossi WE, Godlewski T, Karabenick RL, Stephens JM, Ullrich T, Rice KC, Woods JH. Pharmacological characterization of the effects of 3,4-methylenedioxymethamphetamine ("ecstasy") and its enantiomers on lethality, core temperature, and locomotor activity in singly housed and crowded mice. Psychopharmacology. 166: 202-11. PMID 12563544 DOI: 10.1007/s00213-002-1261-5  1
2002 Fantegrossi WE, Ullrich T, Rice KC, Woods JH, Winger G. 3,4-Methylenedioxymethamphetamine (MDMA, "ecstasy") and its stereoisomers as reinforcers in rhesus monkeys: serotonergic involvement. Psychopharmacology. 161: 356-64. PMID 12073162 DOI: 10.1007/s00213-002-1021-6  1
1998 Etkind SA, Fantegrossi WE, Riley AL. Cocaine and alcohol synergism in taste aversion learning. Pharmacology, Biochemistry, and Behavior. 59: 649-55. PMID 9512067 DOI: 10.1016/S0091-3057(97)00476-0  1
1997 Glowa JR, Fantegrossi WE. Effects of dopaminergic drugs on food- and cocaine-maintained responding. IV: Continuous cocaine infusions Drug and Alcohol Dependence. 45: 71-79. PMID 9179509 DOI: 10.1016/S0376-8716(97)01350-1  1
1996 Glowa JR, Fantegrossi WE, Lewis DB, Matecka D, Rice KC, Rothman RB. Sustained decrease in cocaine-maintained responding in rhesus monkeys with 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-hydroxy-3- phenylpropyl)piperazinyl decanoate, a long-acting ester derivative of GBR 12909 Journal of Medicinal Chemistry. 39: 4689-4691. PMID 8941381 DOI: 10.1021/jm960551t  1
Show low-probability matches.